Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Nov 28, 2022 4:04pm
200 Views
Post# 35134865

RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockwith the anemic volumes traded on this stock, the dribble of shares that are bought and sold on a daily basis are hardly the work of a determined MM hoping to manipulate investors out of their shares.

Noteable., You post non-stop to the point of nausea with thinly related articles. You never answer questions all the while pointing to other bios being bought out for billions, thereby insinuating (manipulating if you like, I'll use your language shall I?) that the same will happen to ONCY. You are such a self righteous muppet.

For over 10 years, ONCY mgmt have been talking partnerships. It just never materialises. If other bios have been bought out for huge sums with just Phase I data,. what is it about ONCY that the market just doesn't want to digest ? Before Matt, good old Brad would state that the company was on the cusp. But never on the cusp of what, success or failure.!! LOL

There are hints of efficacy in so many trials, but yet there is NO proof. IF IND-213 data was so good, then a partner would have been happy to pay for the trial, get it approved and give some hope to so many patients. NOPE.

Whilst you would have all readers believe that the future is all rainbows and unicorns, that future is always another 9 months away. So if my words are manipulative, so be it... just be cautious, and don't put more into this company than you are willing to lose.

FWIW, I don't think they will follow through with a Phase III for mBC. But it would be nice to be wrong (like canadafan with his many years of woefully poor price predictions).

GLTA
<< Previous
Bullboard Posts
Next >>